Heparin Market - Forecast(2024 - 2030)

Heparin Market size is valued at $10.86Bn by 2019, and is anticipated to grow at a CAGR of 7.19% during the forecast period 2020-2025. The Heparin Market growth rate is attributed to the increasing incidences of coagulation disorders, substantial growth in the number of the people suffering from diseases like venous thromboembolism and heart diseases. is used to prevent formation of blood clots caused by certain medical conditions or medical procedures. It is used in the treatment for various health conditions such as acute coronary syndrome, deep-vein thrombosis, pulmonary embolism, atrial fibrillation, and is also used during heart surgery for carrying out cardiopulmonary bypass as well as hemofiltration. From increasing incidence of venous thromboembolism and cardiovascular disorders Increasing incidence of venous thromboembolism and cardiovascular disorders to increase in government funding toward improving healthcare facilities and extensive research and development (R&D) activities to develop heparin with improved therapeutic potential and minimal side-effects is anticipated to propel the Heparin Market during the forecast period 2020-2025.

The report: “Heparin Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Heparin Market:

By Source Type: Mammalian Sources and Non-Mammalian Sources.

By Product Type: High Molecular Weight Heparin, Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin(ULMWH).

By Mode of Administration: Parenteral Administration and Oral Administration.

By Ingredients: Heparin Calcium, Heparin Sodium.

By Applications: Acute Coronary Syndrome, Anticoagulation During Pregnancy, Angina, Antiphospholipid Syndrome, Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis, Heart Attack, Patency Maintenance of Indwelling Intravenous Devices, Pulmonary Embolism, Thrombotic/Thromboembolic Disorder, Venous Thromboembolism.

By Geography: North America, Europe, Asia-Pacific and RoW.

Parenteral Administration segment held the largest share in the market owing to less cost associated with hospitalization. Also this method is preferred over oral mode owing to ease of administration, rising preference for home care and reduced duration of treatment. Moreover, the associated benefits of this route of administration includes low risk of systemic infection and improved quality of life.

On the basis of Application type, deep vein thrombosis segment held the major share of the market in terms of revenue and is poised to grow with a CAGR of 7.1%. The reason is set to be attributed to the increasing awareness of thrombosis such as pulmonary embolism (PE) and deep vein thrombosis (DVT). Increasing prevalence and incidence of heart-related disorders is anticipated to further expand the consumption rate over the projection period of 2020-2025. 

North America dominated the Heparin Market with a share of 39% in 2019. North America remains the largest market owing to the growing awareness among consumers, constant improving healthcare infrastructure, presence of untapped opportunities, economic development, and rising initiatives by private and public organizations continues to expand its market. According to a report published in the American Heart Association, in 2018, around 92.1 million American adults were suffering from some form of cardiovascular disease. In addition, around 1 in every 3 deaths are caused by cardiovascular disease in the U.S. accounting for around 2,300 deaths per day. High initial capital investment on infrastructure, government funding toward improving healthcare facilities and extensive research and development (R&D) activities to develop heparin with improved therapeutic potential are to cater the Heparin Market in the forecast period of 2020-2025.

With the increase in the introduction of various biosimilar LMWH Anticoagulants owing to increasing use in a number of Western European countries and emerging economies and its potential indications, such as thromboprophylaxis, Venous thromboembolism (VTE), anticoagulation treatment during pregnancy, among others. Enoxaparin is the bestselling LMWH worldwide. Therefore, pharmaceutical companies in many countries are focused on producing generic forms of LMWH which is to act as a key driver of the market during the forecast period 2020-2025. 

The major challenge for the market is the high initial capital investment on infrastructure and the requirement of an improved healthcare facility for treatment and compliance in a vast and heterogeneous market. The stringent rules and regulations regarding the processing and preservation prior to distribution and sales is the major problem for some of the regions in Asia-Pacific. 

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Heparin Market. In 2019, Heparin Market share is fragmented by the top ten players present in the market. Heparin Market top 10 companies are LEO Pharma A/S, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Novartis AG, Sanofi, Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Aspen Holdings, changzhaou Qianhong Bio-pharma Co., ltd., Eisai Co., Ltd., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, and others.